logo-loader
viewInnate Immunotherapeutics Ltd

Innate Immunotherapeutics to join key Multiple Sclerosis consortium

au_medical_350_5546d1d3f3c1a.jpg

Innate Immunotherapeutics Limited (ASX:IIL) will join a consortium for Multiple Sclerosis research funded by the U.S. National MS Society and led by the Critical Path Institute.

The Multiple Sclerosis Outcome Assessments Consortium is an American based consortium undertaking the development of a clinical outcome assessment tool for use in future MS clinical trials.

Such a tool, which could comprise a number of clinical tests, would improve and speed the evaluation of new therapies for progressive MS, in particular.

For Innate Immunotherapeutics, a start-up company this is a sizeable step to take its place among academia, industry, regulatory authorities, and patient advocacy groups to generate evidence needed to improve the drug development pathway.

MSOAC is funded by C-Path, a US-based body which orchestrates the sharing of data and expertise among these groups.

The consortium includes clinicians and researchers at leading academic institutions in North America, the UK, and Europe.

It also has as its members pharmaceutical companies active in the development of MS-related therapies, regulators including the FDA and the European Medicines Agency, and patient advocacy groups.

Clinical Trial

Innate Immunotherapeutics has a Phase 2B clinical trial of its MIS416 drug candidate to treat patients with secondary progressive multiple sclerosis (SPMS) that it is enrolling patients.

Currently 22 patients, being 25% of the targeted 90 trial subjects, have been enrolled into the trial.

Innate Immunotherapeutics Limited (ASX:IIL) will join a consortium for Multiple Sclerosis research funded by the U.S. National MS Society and led by the Critical Path Institute.

The Multiple Sclerosis Outcome Assessments Consortium is an American based consortium undertaking the development of a clinical outcome assessment tool for use in future MS clinical trials.

Such a tool, which could comprise a number of clinical tests, would improve and speed the evaluation of new therapies for progressive MS, in particular.

For Innate Immunotherapeutics, a start-up company this is a sizeable step to take its place among academia, industry, regulatory authorities, and patient advocacy groups to generate evidence needed to improve the drug development pathway.

MSOAC is funded by C-Path, a US-based body which orchestrates the sharing of data and expertise among these groups.

The consortium includes clinicians and researchers at leading academic institutions in North America, the UK, and Europe.

It also has as its members pharmaceutical companies active in the development of MS-related therapies, regulators including the FDA and the European Medicines Agency, and patient advocacy groups.

Clinical Trial

Innate Immunotherapeutics has a Phase 2B clinical trial of its MIS416 drug candidate to treat patients with secondary progressive multiple sclerosis (SPMS) that it is enrolling patients.

Currently 22 patients, being 25% of the targeted 90 trial subjects, have been enrolled into the trial.

Innate Immunotherapeutics Limited (ASX:IIL) will join a consortium for Multiple Sclerosis research funded by the U.S. National MS Society and led by the Critical Path Institute.

The Multiple Sclerosis Outcome Assessments Consortium is an American based consortium undertaking the development of a clinical outcome assessment tool for use in future MS clinical trials.

Such a tool, which could comprise a number of clinical tests, would improve and speed the evaluation of new therapies for progressive MS, in particular.

For Innate Immunotherapeutics, a start-up company this is a sizeable step forward to take its place among academia, industry, regulatory authorities, and patient advocacy groups to generate evidence needed to improve the drug development pathway.

MSOAC is funded by C-Path, a US-based body which orchestrates the sharing of data and expertise among these groups.

The consortium includes clinicians and researchers at leading academic institutions in North America, the UK, and Europe.

It also has as its members pharmaceutical companies active in the development of MS-related therapies, regulators including the FDA and the European Medicines Agency, and patient advocacy groups.

Clinical Trial

Innate Immunotherapeutics has a Phase 2B clinical trial of its MIS416 drug candidate to treat patients with secondary progressive multiple sclerosis (SPMS) that it is enrolling patients.

Currently 22 patients, being 25% of the targeted 90 trial subjects, have been enrolled into the trial.

The company had over $4.1 million at March quarter 2015 end.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Innate Immunotherapeutics Ltd

Price: - -

ASX:IIL
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Delecta hones in on Copper Ridge in Utah and outlines exploration steps

Delecta Limited (ASX:DLC) technical director Greg Smith updates Proactive on the newly acquired Copper Ridge project in Utah, USA, and next steps in the exploration program.  The Copper Ridge acquisition covers four historical copper mines and prospects. Delecta's acquisition also...

38 minutes ago

4 min read